305 related articles for article (PubMed ID: 29285812)
1. Are government-approved products containing new psychoactive substances perceived to be safer and more socially acceptable than alcohol, tobacco and illegal drugs? Findings from a survey of police arrestees in New Zealand.
Rychert M; Wilkins C; Parker K; Witten K
Drug Alcohol Rev; 2018 Mar; 37(3):406-413. PubMed ID: 29285812
[TBL] [Abstract][Full Text] [Related]
2. Do police arrestees substitute legal highs for other drugs?
Wilkins C; Parker K; Prasad J; Jawalkar S
Int J Drug Policy; 2016 May; 31():74-9. PubMed ID: 26948501
[TBL] [Abstract][Full Text] [Related]
3. Issues with monitoring the safety of psychoactive products under a legal regulated market for new psychoactive substances ('legal highs') in New Zealand.
Rychert M; Wilkins C; Witten K
Drug Alcohol Rev; 2017 Sep; 36(5):589-596. PubMed ID: 28229493
[TBL] [Abstract][Full Text] [Related]
4. A critical first assessment of the new pre-market approval regime for new psychoactive substances (NPS) in New Zealand.
Wilkins C
Addiction; 2014 Oct; 109(10):1580-6. PubMed ID: 24529166
[TBL] [Abstract][Full Text] [Related]
5. An exploratory study of the health harms and utilisation of health services of frequent legal high users under the interim regulated legal high market in central Auckland.
Wilkins C; Prasad J; Wong KC; Rychert M; Graydon-Guy T
N Z Med J; 2016 Mar; 129(1431):51-8. PubMed ID: 27005874
[TBL] [Abstract][Full Text] [Related]
6. Legal high industry business and lobbying strategies under a legal market for new psychoactive substances (NPS, 'legal highs') in New Zealand.
Rychert M; Wilkins C
Int J Drug Policy; 2016 Nov; 37():90-97. PubMed ID: 27639994
[TBL] [Abstract][Full Text] [Related]
7. A critical analysis of the implementation of a legal regulated market for new psychoactive substances ("legal highs") in New Zealand.
Rychert M; Wilkins C
Int J Drug Policy; 2018 May; 55():88-94. PubMed ID: 29524738
[TBL] [Abstract][Full Text] [Related]
8. Understanding the development of a regulated market approach to new psychoactive substances (NPS) in New Zealand using Punctuated Equilibrium Theory.
Rychert M; Wilkins C
Addiction; 2018 Nov; 113(11):2132-2139. PubMed ID: 29744945
[TBL] [Abstract][Full Text] [Related]
9. The challenge of a ban on animal testing for the development of a regulated legal market for new psychoactive substances (NPS) ('legal highs') in New Zealand: Issues and options for resolution.
Rychert M; Wilkins C
Int J Drug Policy; 2015 Dec; 26(12):1273-8. PubMed ID: 26364077
[TBL] [Abstract][Full Text] [Related]
10. "They're legal so they're safe, right?" What did the legal status of BZP-party pills mean to young people in New Zealand?
Sheridan J; Butler R
Int J Drug Policy; 2010 Jan; 21(1):77-81. PubMed ID: 19321329
[TBL] [Abstract][Full Text] [Related]
11. What products are considered psychoactive under New Zealand's legal market for new psychoactive substances (NPS, 'legal highs')? Implications for law enforcement and penalties.
Rychert M; Wilkins C
Drug Test Anal; 2016 Aug; 8(8):768-78. PubMed ID: 26857892
[TBL] [Abstract][Full Text] [Related]
12. Driving under the influence among frequent ecstasy consumers in Australia: trends over time and the role of risk perceptions.
Matthews AJ; Bruno R; Dietze P; Butler K; Burns L
Drug Alcohol Depend; 2014 Nov; 144():218-24. PubMed ID: 25282306
[TBL] [Abstract][Full Text] [Related]
13. Do novel psychoactive substances displace established club drugs, supplement them or act as drugs of initiation? The relationship between mephedrone, ecstasy and cocaine.
Moore K; Dargan PI; Wood DM; Measham F
Eur Addict Res; 2013; 19(5):276-82. PubMed ID: 23615495
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of the use of 3-MMC and other new psychoactive drugs in Slovenia, and the perceived problems experienced by users.
Sande M
Int J Drug Policy; 2016 Jan; 27():65-73. PubMed ID: 25908121
[TBL] [Abstract][Full Text] [Related]
15. The rise of new psychoactive substance use in Australia.
Burns L; Roxburgh A; Matthews A; Bruno R; Lenton S; Van Buskirk J
Drug Test Anal; 2014; 6(7-8):846-9. PubMed ID: 24599890
[TBL] [Abstract][Full Text] [Related]
16. Patterns and correlates of new psychoactive substance use in a sample of Australian high school students.
Champion KE; Teesson M; Newton NC
Drug Alcohol Rev; 2016 May; 35(3):338-44. PubMed ID: 26194894
[TBL] [Abstract][Full Text] [Related]
17. Typology of new psychoactive substance use among the general Australian population.
Sutherland R; Peacock A; Roxburgh A; Barratt MJ; Burns L; Bruno R
Drug Alcohol Depend; 2018 Jul; 188():126-134. PubMed ID: 29775956
[TBL] [Abstract][Full Text] [Related]
18. The diverse reasons for using Novel Psychoactive Substances - A qualitative study of the users' own perspectives.
Soussan C; Andersson M; Kjellgren A
Int J Drug Policy; 2018 Feb; 52():71-78. PubMed ID: 29241144
[TBL] [Abstract][Full Text] [Related]
19. New psychoactive substances: issues about the new approach from New Zealand government.
von Diemen L
Addiction; 2014 Oct; 109(10):1588-9. PubMed ID: 25163704
[No Abstract] [Full Text] [Related]
20. Harms associated with psychoactive substances: findings of the UK National Drug Survey.
Morgan CJ; Muetzelfeldt L; Muetzelfeldt M; Nutt DJ; Curran HV
J Psychopharmacol; 2010 Feb; 24(2):147-53. PubMed ID: 19939875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
